miRNA and Gemcitabine Response REFERENCES 1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. 2. Hirata K, Egawa S, Kimura Y, et al. Current status of surgery for pancreatic cancer. Dig Surg. 2007;24:137–47. 3. Hawes RH, Xiong Q, Waxman I, Chang KJ, Evans DB, Abbruzzese JL. A multispecialty approach to the diagnosis and management of pancreatic cancer. Am J Gastroenterol. 2000; 95:17–31. 4. Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic Cancer Registry in Japan: 20 years of experience. Pancreas. 2004;28: 219–30. 5. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pan- creatic cancer. N Engl J Med. 2004;350:1200–10. 6. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007;297:267–77. 7. Heinemann V, Hertel LW, Grindey GB, Plunkett W. Compari- son of the cellular pharmacokinetics and toxicity of 20,20-dif- luorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res. 1988;48:4024–31. 8. Burris HA III, Moore MJ, Andersen J, et al. Improvements in survival and clinical beneﬁt with gemcitabine as ﬁrst-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13. 9. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcita- bine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6. 10. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol. 2009;27: 2231–7. 11. Farrell JJ, Elsaleh H, Garcia M, et al. Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology. 2009;136: 187–95. 12. Nakano Y, Tanno S, Koizumi K, et al. Gemcitabine chemore- sistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer. 2007;96:457–63. 13. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45. 14. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identiﬁ- cation of novel genes coding for small expressed RNAs. Science. 2001;294:853–8. 15. Lau NC, Lim LP, Weinstein EG, Bartel DP. An abundant class of tiny RNAs with probable regulatory roles in Caenorhabditis elegans. Science. 2001;294:858–62. 16. Li J, Smyth P, Flavin R, et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-ﬁxed parafﬁn-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol. 2007;7:36. 2387 17. Xi Y, Nakajima G, Gavin E, et al. Systematic analysis of micr- oRNA expression of RNA extracted from fresh frozen and formalin-ﬁxed parafﬁn-embedded samples. RNA. 2007;13: 1668–74. 18. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nons- quamous non-small-cell lung carcinoma. J Clin Oncol. 2009;27: 2030–7. 19. Bloomston M, Frankel WL, Petrocca F, et al. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007;297: 1901–8. 20. Xie Y, Todd NW, Liu Z, et al. Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer. 2010;67:170–6. 21. Greither T, Grochola L, Udelnow A, Lautenschlager C, Wurl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumours associates with poorer survival. Int J Cancer. 2010;126(1):73-80. 22. Dillhoff M, Liu J, Frankel W, Croce C, Bloomston M. MicroR- NA-21 is overexpressed in pancreatic cancer and a potential predictor of survival. J Gastrointest Surg. 2008;12:2171–6. 23. Ohuchida K, Mizumoto K, Murakami M, et al. Radiation to stromal ﬁbroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res. 2004;64: 3215–22. 24. Hamilton R, Gray C, Belanger SA, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry. J Can Acad Child Adolesc Psychiatry. 2009;18:349–55. 25. Sobin C, Gutierrez M, Alterio H. Polymorphisms of delta-am- inolevulinic acid dehydratase (ALAD) and peptide transporter 2 (PEPT2) genes in children with low-level lead exposure. Neu- rotoxicology. 2009;30:881–7. 26. Hoffmann AC, Mori R, Vallbohmer D, et al. High expression of HIF1a is a predictor of clinical outcome in patients with pan- creatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia. 2008;10:674–9. 27. Liu X, Sempere LF, Galimberti F, et al. Uncovering growth- suppressive microRNAs in lung cancer. Clin Cancer Res. 2009; 15:1177–83. 28. Chen L, Yan HX, Yang W, et al. The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma. J Hepatol. 2009;50:358–69. 29. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblas- toma cells. Oncogene. 2007;26:5017–22. 30. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-sup- pressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA. 2007;104:15472–7. 31. Gallardo E, Navarro A, Vinolas N, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–9.